{"id":"docetaxel-xrp6976","safety":{"commonSideEffects":[{"rate":"75–80","effect":"Neutropenia"},{"rate":"50–60","effect":"Anemia"},{"rate":"25–35","effect":"Thrombocytopenia"},{"rate":"20–30","effect":"Peripheral neuropathy"},{"rate":"75–80","effect":"Alopecia"},{"rate":"30–40","effect":"Nausea/vomiting"},{"rate":"40–50","effect":"Fatigue"},{"rate":"5–10","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel is a taxane that binds to the β-subunit of tubulin dimers and promotes microtubule assembly while inhibiting disassembly. This leads to accumulation of stable microtubules and disruption of the dynamic microtubule network required for cell division, ultimately triggering apoptosis in cancer cells. It is effective against a broad range of solid tumors.","oneSentence":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:44.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"},{"name":"Gastric cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT01515748","phase":"PHASE3","title":"Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12-30","conditions":"Gastric Cancer","enrollment":530},{"nctId":"NCT01308567","phase":"PHASE3","title":"Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05-05","conditions":"Prostate Cancer","enrollment":1168},{"nctId":"NCT01718353","phase":"PHASE2","title":"Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Prostate Cancer Metastatic","enrollment":63},{"nctId":"NCT02061631","phase":"PHASE2","title":"Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-05","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":35},{"nctId":"NCT00565448","phase":"PHASE2","title":"Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-11","conditions":"Nasopharyngeal Neoplasms, Carcinoma","enrollment":75},{"nctId":"NCT01576029","phase":"PHASE2","title":"Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Prostatic Neoplasms","enrollment":2},{"nctId":"NCT00514917","phase":"PHASE3","title":"A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Prostatic Neoplasms","enrollment":413},{"nctId":"NCT01907685","phase":"PHASE1","title":"Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Advanced Neoplastic Disease","enrollment":58},{"nctId":"NCT00917748","phase":"PHASE3","title":"Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Prostatic Neoplasms, Breast Cancer","enrollment":84},{"nctId":"NCT01148615","phase":"PHASE1","title":"A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Neoplasm Malignant","enrollment":20},{"nctId":"NCT00401323","phase":"PHASE2, PHASE3","title":"Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"1998-01","conditions":"Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis","enrollment":568},{"nctId":"NCT00723086","phase":"PHASE2","title":"Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Therapy, Prostatic Neoplasms","enrollment":16},{"nctId":"NCT00916097","phase":"PHASE2","title":"NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-07","conditions":"Head and Neck Neoplasms","enrollment":66},{"nctId":"NCT00273546","phase":"PHASE3","title":"Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"1999-05","conditions":"Cancer","enrollment":500},{"nctId":"NCT00290966","phase":"PHASE2, PHASE3","title":"Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"1998-10","conditions":"Stomach Neoplasm","enrollment":610}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere®","Taxotere"],"phase":"phase_3","status":"active","brandName":"Docetaxel (XRP6976)","genericName":"Docetaxel (XRP6976)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}